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Abstract
To promote and support tendon healing, one viable strategy is the use or administration of growth factors at 
the wound/rupture site. Platelet derived growth factor-BB (PDGF-BB), together with other growth factors, is 
secreted by platelets after injury. PDGF-BB promotes mitogenesis and angiogenesis, which could accelerate 
tendon healing. Therefore, in vitro studies with PDGF-BB have been performed to determine its effect on 
tenocytes and tenoblasts. Moreover, accurate and sophisticated drug delivery devices, aiming for a sustained 
release of PDGF-BB, have been developed, either by using heparin-binding and fibrin-based matrices or dif-
ferent electrospinning techniques.
 In this review, the structure and composition, as well as the healing process of tendons, are described. 
Part A deals with in vitro studies. They focus on the multiple effects evoked by PDGF-BB on the cellular level. 
Moreover, they address strategies for the sustained delivery of PDGF-BB. Part B focuses on animal models 
used to test different delivery strategies for PDGF-BB, in the context of tendon reconstruction. These studies 
showed that dosage and timing of PDGF-BB application are the most important factors for deciding which 
delivery device should be applied for a specific tendon laceration.
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Introduction
The healing of acutely injured tendons is a lengthy 
process, due to the inherent characteristics of these 
connective tissues. A poor vascular network and cells 
with low metabolic rate add to the poor intrinsic 
healing capacities andlimited regenerative potential 
of tendons. Often, the healing process is accompanied 
by development of a scar tissue next to properly 
regenerated tissue (Galatz et al., 2015). The fibrous 
scar tissue has inferior properties compared to 
native tissue, resulting in functional and mechanical 
insufficiencies (Elliot and Giesen, 2013a). Biological 
therapies may help to overcome these problems. One 
approach, investigated to support tendon repair both 
in vitro and in vivo, is the application of growth factors 
(Bissell et al., 2014; Hsu and Chang, 2004), including 
platelet-derived growth factor-BB (PDGF-BB) (Hee 
et al., 2012).
 PDGF-BB is part of the PDGF growth factor 
family, which includes four isoforms (A, B, C and 
D) (Andrae et al., 2008). The PDGF-BB dimer – the 
mostly investigated isoform – is the only one that 
can bind to all three different surface PDGF receptors 
(PDGFRs) and trigger different signalling cascades, 
thus being called the universal isoform of PDGF. 
Compared to other growth factors, PDGF-BB has 
a well-established safety profile, approved by the 
Food and Drug Administration (FDA) (Borena et al., 
2015), and formulations supporting wound healing 
in foot ulcers, as well as, bone regeneration are on the 
market [Regranex Gel® (Smith&Nephew, London, 
UK) and GEM 21S® (Luitpold, Pharmaceuticals, 
Shirley, NY, USA)] (Howard et al., 2014; Ma et al., 
2015). In chronic foot ulcers, topical application of 
rhPDGF led to a significant increase (by 43 %) in the 
incidence of complete wound closure and decrease 
in healing time (by 32 %) over placebo-controlled 
wound care, resulting in the FDA approval of 
Regranex Gel® (Wieman et al., 1998). The effect of 
PDGF-BB in supporting osteogenic differentiation 
has been shown in an in vitro study with MG63 cells 
(Vahabi et al., 2016). In addition, positive clinical 
results for GEM 21S® were reported in regenerative 
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periodontal surgery (Singh and Suresh, 2012). 
Moreover, platelet-rich plasma (PRP), blood plasma 
enriched with platelets, which release different 
growth factors (including PDGF-BB) upon activation 
by thrombin, has also been reported to be beneficial 
in a clinical setting [see reviews about PRP use in 
patellar tendinopathy (Jeong et al., 2014) and PRP 
use in medical collateral ligament injuries (Andia 
and Maffulli, 2015)]. Injection of PRP has been 
shown to be superior to shock wave therapy when 
treating jumper’s knee (patellar tendon or quadriceps 
tendon) (Vetrano et al., 2013) and to reduce donor 
site morbidity in patellar tendons (de Almeida et 
al., 2012). However, one big disadvantage of PRP 
is its variability in composition, due to different 
preparation protocols and patient differences, 
resulting in different effects with regard to growth 
factor composition and release (Marques et al., 2015; 
Schaer et al., 2015). Hence, mixed outcomes in clinical 
settings resulted after PRP application (Castillo et al., 
2011; de Vos et al., 2010; Eppley et al., 2004; Foster 
et al., 2009; Kevy and Jacobson, 2004; Nikolidakis 
and Jansen, 2008). Therefore, a defined mixture of 
growth-factors or one single growth factor like PDGF-
BB delivered in a controlled way present a good 
alternative for eliminating variability in treatment 
outcomes.
 The functions of PDGF during tendon healing 
are manifold. After blood clot formation, platelets 
(thrombocytes) release a series of growth factors that 
interact with each other (Anitua et al., 2007). PDGF 
attracts inflammatory cells, such as neutrophils 
and macrophages, responsible for the breakdown 
and phagocytosis of the debris (Deuel et al., 1982; 
Inaba et al., 1993; Tzeng et al., 1985). Also, PDGF 
attracts tenocytes and fibroblasts that migrate to 
the wound site and start synthesising extracellular 
matrix components, including collagen (Banes et 
al., 1995; Siegbahn et al., 1990; Spindler et al., 1995; 
Thomopoulos et al., 2005).
 When PDGF-BB is applied as a biological 
therapy, the time point of application and the 
dosage significantly impact its effectiveness. As 
the endogenous release of PDGF-BB is during the 
inflammatory and early proliferative phase (Chen et 
al., 2008; Gulotta and Rodeo, 2009; Wuergler-Hauri 
et al., 2007), it should be administered within the 
first two weeks after injury, at best using a delivery 
method that allows a controlled and sustained 
release. So far, clinical use of PDGF-BB in the tendon 
repair field has not been reported, with the main issue 
represented by its administration, i.e. providing a 
reliable delivery system that will allow for a sustained 
delivery of bioactive PDGF-BB at the injured site.
Fig. 1. General overview of the tendon healing process. After injury, several different, overlapping phases 
[inflammatory, reparative (proliferative), remodelling and later modelling phase] comprise the process 
of tendon healing, each one lasting for a shorter (hours) or longer (weeks) time period and marked with 
specific molecular, cellular and tissue changes. The length of each phase can differ in different species. 
The initial two phases (within 1-2 weeks post-injury) would be the most suitable time for the application 
of a construct delivering bioactive PDGF at the site of repair (Docheva et al., 2015; Molloy et al., 2003; 
Sharma and Maffulli, 2006).
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Materials and Methods
Approximately 60 % of the papers mentioned in 
this review (total number of papers included in this 
review: 175) were found by a search in the Web of 
Knowledge/Web of Science/Google Scholar databases 
using the key words “tendon AND PDGF OR platelet 
derived growth factor”; “tenocyte AND PDGF 
OR platelet derived growth factor”; “PDGF AND 
sustained delivery”; “PDGF AND electrospinning” 
(the search was performed during the period of 
February-August 2016 and only literature written in 
English was reviewed). The remaining 40 % were cited 
in the references found within this search; with the 
exception of some very recent papers. The reviewed 
literature was published from 1978 to 2016. Original 
research papers, communications, review papers, 
as well as book chapters, were included. We focused 
on PDGF-BB administration to lacerated tendons, 
either by single bolus injections or released in a 
sustained manner from a delivery device. Moreover, 
full transections of tendons, partial lacerations and 
tendinopathy animal models, such as collagenase-
induced tendinopathy, were included and the effects 
of PDGF-BB on the healing pattern were discussed. 
This review is divided into two main parts (A and B): 
in vitro and in vivo preclinical experiments.
Composition and healing of tendons
Tendons are constituted of fibres comprised of 
crosslinked collagen fibrils. Several different cell 
populations reside between chains of these long 
and parallel fibrils, including tenocytes (Lui, 
2013), their precursor cells are called tenoblasts 
and tendon stem/progenitor cells (Bi et al., 2007; 
Kannus, 2000). Tenocytes, spindle-shaped and 
elongated, are the most numerous cell population 
and they are responsible for the formation/turnover 
of extracellular matrix, assembly of early collagen 
fibres and facilitation of collagen network adaptation 
to external stimuli (Milz et al., 2009). Tenoblasts, 
on the other hand, can vary in size and shape and 
are considered to be responsible for matrix (tissue) 
remodelling (Chuen et al., 2004). Tendon stem/
progenitor cells have been recently discovered and 
their capacity to differentiate into bone, cartilage or 
fat has been observed (Bi et al., 2007), as well as, the 
expression of certain stem cells markers (Oct4 and 
SSEA4 among others) (Lui and Chan, 2011; Zhang 
and Wang, 2010b). The percentage of tendon stem/
progenitor cells depends on age, species and type 
of tendon: younger specimens contain a higher 
percentage of tendon stem/progenitor cells (Zhou 
et al., 2010) and the functional fitness of the cells is 
higher when compared to aged specimens (Spindler 
et al., 1995).
 The cell population, present within tendons, 
synthesises their necessary extracellular components, 
mainly collagens, glycosaminoglycans (GAGs), 
proteoglycans and elastin, and the composition varies 
slightly between tendons found in different locations 
of the body. Collagen fibres serve to maintain the 
tissue architecture, transmission and absorption of 
load and prevention of damage during mechanical 
stress (Pins et al., 1997). Collagen type I (Col I) is 
the major extracellular matrix (ECM) constituent, 
roughly 65-80 % of the tendon dry mass (Kannus, 
2000). Collagen type III (Col III) is the second most 
abundant collagen molecule and, although restricted 
to tendon sheets, it is the first collagen produced 
during tendon healing (Fig. 1) and is present in 
larger amounts in pathological tendons (Riley, 2004). 
Other collagen types in tendons include collagen 
type V, VI, XII, XIV and XV (Docheva et al., 2015). 
In addition, elastic fibres composed of elastin and 
fibrillin are broadly distributed throughout tendons, 
with longitudinal localisation around cells and 
transversal localisation between collagen fascicles 
(Giusti and Pepe, 2016; Grant et al., 2013; Kielty et al., 
2002). They allow tendon’s extendibility and elasticity 
and are thought to play a role in the reestablishment 
of the crimp pattern of collagen fibres after tendon 
stretching (Butler et al., 1978).
 Even though mature tendons are characterised 
by low cellular density (~ 20 % of the total tissue 
volume; Nordin et al., 2001), the cell population 
within the tendon is immediately affected upon 
tendon injury/damage. The healing process of 
tendons follows several phases, each characterised 
by different molecular elements and mechanisms 
(Fig. 1). Immediately after injury, a mix of cytokines 
and growth factors is released from the platelets and 
inflammatory cells,-such as macrophages, monocytes 
and neutrophils, attracted to the wound site (Fig. 2) 
and produce tumour necrosis factor (TNF) or growth 
factors involved in neovascularisation, such as 
vascular endothelial growth factor (VEGF), fibroblast 
growth factor (FGF) and PDGF (Chazaud, 2014; Lynch 
et al., 1987). During healing, fibrin clot formation 
serves as a provisional scaffold, releasing a variety of 
growth factors, aiding the healing process. However, 
occasionally, this provisional scaffold is missing, as 
in the healing of anterior cruciate ligaments (ACL), 
and has been pointed out as a reason why the ACL 
does not have innate healing capacity (Murray et al., 
2000; Murray et al., 2007; Murray and Fleming, 2013). 
The inflammatory phase takes place within the first 
hours after injury. It is followed by a proliferative, i.e. 
reparative, phase during which, fibroblasts, recruited 
from the tendon sheath and tendon, proliferate as a 
result of the mix of growth factors [ transforming 
growth factor beta (TGFβ), FGF, Insulin-like growth 
factor 1 (IGF-1), PDGF and VEGF] produced at the 
wound site, and afterwards start synthesising ECM 
components, like collagen – predominantly type III – 
and proteoglycans. Angiogenesis, even though it may 
be thought as haphazard, is essential and beneficial, 
since lack of blood supply can impair the healing 
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process. Later, this transient capillary network has 
to retract so that the healing process can progress 
properly (Fenwick et al., 2002).
 In the next stage, remodelling of the tissue takes 
place by decrease of the cellular and vascular content 
and subsequent increase in deposition of collagen 
type I. Water content and glycosaminoglycan 
amounts stay larger in this phase (Oakes, 2008). In 
the modelling phase (consolidation + maturation), 
disorganised and randomly oriented collagen fibres 
are reorganised and healing tissue is reshaped and 
resized. During consolidation, the tissue changes 
from cellular to fibrous, synthesis of collagen type 
I still takes place and the collagen fibres become 
aligned in the direction of the stress (Hooley and 
Cohen, 1979). In the final stage, collagen fibril 
crosslinking is increased and the tissue changes 
gradually from fibrous to scar-like tendon tissue. 
The functionality after the healing is not the same as 
the one of a native tendon, due to structural aspects, 
i.e. alignment of collagen fibres, level of collagen 
cross-linking and natural crimp of collagen fibres 
differ from the native tendon (Connizzo et al., 2013). 
In order to re-establish this aspect, proper tissue 
organisation, i.e. collagen fibre organisation, needs 
to be addressed and improved. Changes in elastic 
fibres during tendon healing have not been studied 
in detail yet, but initial evidence suggests that there 
is an increase in fibrillin-1 synthesis accompanied 
with a small increase in elastin production (Thakkar 
et al., 2014). How this translates directly to the 
functional aspects of healed tendons is not clear yet. 
With regards to the cellular mechanism involved in 
tendon healing, it is believed that two mechanisms 
act together, intrinsic healing and extrinsic healing 
(Fenwick et al., 2002; Kajikawa et al., 2007). Initially, 
fibroblasts and inflammatory cells, from the tendon 
periphery and blood, are activated and migrate to 
the injury site, thus contributing to cell infiltration/
adhesion formation and constituting the extrinsic 
mechanism (Beredjiklian, 2003). Later, the intrinsic 
mechanism takes place with cells from the endotenon 
being activated and migrating to the injury site, where 
they proliferate, synthesise ECM and play a role in 
its reorganisation (James et al., 2008; Lin et al., 2004). 
Indeed, one study has shown that the healing is a 
biphasic pattern (Kajikawa et al., 2007).
 The development of scar-like tendon tissue during 
healing leads to inferior mechanical, structural and 
biological properties, compared to non-injured 
tendons. For this reason, it has been proposed that 
application of bioactive constructs or injectable 
systems should aim at stimulating the intrinsic 
and suppressing the extrinsic healing mechanism 
to get improved restoration of the mechanical and 
functional properties of the healed tendons (Lomas 
Fig. 2. Release and mechanism 
of action of PDGF after tendon 
injury. After an acute tendon injury, 
growth factors, such as transforming 
growth factor-β (TGF-β), vascular 
endothelial growth factor (VEGF), 
fibroblast growth factor (FGF), 
platelet derived growth factor 
(PDGF) and insulin like growth factor 
(IGF), are released from α-granules 
secreted by platelets at the wound 
site. PDGF upregulates VEGF and 
expression of integrins involved in 
smooth muscle cell migration, thus 
promoting angiogenesis. PDGF 
has chemotactic and mitogenic 
effects on neutrophils, macrophages 
and phagocytes, responsible for 
breakdown and cleaning of tissue 
debris, as well as, on tenocytes that 
enter the wound site to regenerate the 
damaged tissue. As a result, delivery 
of PDGF at the wound site can 
positively affect collagen deposition 
and crosslinking, biomechanical 
properties of a healing tendon, and 
also increase transient vascularisation 
by providing extrinsic factors for 
tendon repair.
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et al., 2015; Tang, 2005). However, achieving good 
tendon regeneration, with proper tissue organisation 
and without any trans-differentiation of tenocytes 
into fibrocartilaginous or bone tissue (de Mos et al., 
2007; Zhang and Wang, 2010a), allowing proper 
tendon function and mechanical properties, still 
represents a major challenge when considering any 
biological strategy for tendon repair.
PDGF-BB is predominantly expressed during 
tendon healing
The pathways regulating normal tendon development 
are not completely understood, but it has been 
shown that FGF, TGFβ and growth differentiation 
factor (GDF) signalling regulate different aspects 
of tenogenesis. So far, PDGF involvement in 
tendon development has not been described. TGFβ 
(specifically TGFβ2/3) and FGF (specifically FGF4 
and FGF8) signalling are shown to play a role in 
collagen expression/synthesis during development 
and in adult life (Brent and Tabin, 2004; Kuo et al., 
2008; Mikic et al., 2006; Paxton et al., 2012; Yun et al., 
2010). Tendon differentiation is mediated through 
the Smad signalling pathway of TGFβ (Lorda-Diez 
et al., 2009; Pryce et al., 2009). Disruption of FGF and 
TGFβ signalling leads to expression inhibition of 
the tendon associated transcription factor scleraxis 
(Scx) (Brent and Tabin, 2004; Brent et al., 2005; Edom-
Vovard et al., 2002; Pryce et al., 2009). Scx is a basic 
helix-loop-helix transcription factor, involved in 
regulating expression of other tenogenic markers 
such as tenascin-C, tenomodulin, Mohawk and 
type I collagen. It is expressed in tendon progenitor 
cells during embryonic development, as well as in 
mature tenocytes (Schweitzer et al., 2001). Recently, 
the important role of Scx in tendon healing has 
been shown through the implantation of scleraxis-
programmed tendon progenitors (hMSC-Scx), which 
enhanced the repair of a full-size rat Achilles tendon 
lesion (Hsieh et al., 2016). Although some key players 
and pathways of tendon development are known, still 
many aspects remain unclear and need to be further 
investigated.
 On the other hand, the growth factor profile 
during tendon healing differs from the one of tendon 
development (Glass et al., 2014). Transforming 
growth factor beta 1 (TGFβ1) is present instead of 
TGFβ2/3, which in turn can activate IGF-1 secretion 
and, thus, have an impact on the functional recovery 
of the tendon (Chang et al., 2000a; Klein et al., 2002). 
PDGF and bone morphogenetic protein 12 (BMP-
12) are moderately expressed overtime in the mid-
substance of the tendon (Wuergler-Hauri et al., 2007). 
Secreted by the platelets, FGF is also released at 
the wound site. The signalling pathways involved 
in development, TGFβ-Smad2/3 and FGF-ERK/
MAPK , are also activated during the healing process 
(Nourissat et al., 2015); however, it needs to be further 
elucidated as to how they interact or integrate during 
these two processes. Increase in mRNA levels of 
genes encoding for collagen, tenomodulin, tenascin-C 
and proteoglycans are observed during tendon 
healing, as well as upregulated expression of Scx and 
Mohawk right after injury (Juneja et al., 2013; Scott 
et al., 2011). The timing of all these cellular events is 
poorly understood. During the inflammatory phase 
and beginning of proliferative phase of the healing 
process, different isomers of PDGF are released from 
the platelets at the wound site (Andrae et al., 2008). 
 PDGF-BB is a homodimer and one of the four 
isoforms (A, B, C and D) of the PDGF growth family. 
There are three cell-surface receptors through which 
PDGF signalling cascade takes place (PDGFRαα, 
PDGFRαβ and PDGFRββ) (Andrae et al., 2008) (Fig. 
3A). Once bound to its receptor, PDGF-BB initiates 
a signalling cascade and different cellular processes 
are affected through different signalling pathways 
(Fig. 3B). Some of the induced signalling pathways 
include Ras-MAPK, phosphoinositide 3-kinase 
(PI3K), phospholipase C gamma (PLCγ) and Janus 
kinase (JAK), which are involved in several cellular 
and developmental processes (Fig. 3B). For a 
comprehensive overview on the signalling pathways 
through which PDGF-BB elicits downstream 
cascades, refer to previous reviews on the topic 
(Andrae et al., 2008; Heldin and Westermark, 1999; 
Tallquist and Kazlauskas, 2004). PDGFR can also 
interact with integrins, through the Na+/H+ exchanger 
regulatory factors (NHERFs) that link it to focal 
adhesion kinase and cytoskeleton (James et al., 2004; 
Veevers-Lowe et al., 2011). In turn, PDGFRs can be 
also affected by the ECM components (DeMali et al., 
1999; Veevers-Lowe et al., 2011).
 The tissue repair mechanisms induced upon 
PDGF-BB delivery are carried through its generic 
chemotactic, mitogenic and angiogenic properties, 
as well as its synergistic actions with other growth 
factors (Deuel et al., 1991; Lynch et al., 1987; Pierce 
et al., 1991). PDGF has chemotactic and mitogenic 
effects on neutrophils, macrophages and phagocytes, 
responsible for breakdown and cleaning of tissue 
debris, as well as on tenocytes that enter the 
wound site to regenerate the damaged tissue. We 
believe that its ability to stimulate tenocyte and 
tenoblast proliferation, collagen production, collagen 
crosslinks and some new vessel formation, can aid 
the tendon healing process in the initial stages and 
lead to a better tissue organisation and subsequently 
improved biomechanical properties. The proliferative 
effect on tenocytes and tenoblasts supports the 
intrinsic healing mechanism, by attracting these cell 
populations from the endotenon, which in turn can 
synthesise and remodel the ECM. On the other hand, 
there is an evidence that the effect of PDGF-BB on 
elastin synthesis is inhibitory, where the MAPK/ERK 
signalling pathway acts in opposition to canonical 
TGFβ1 signalling (Sproul and Argraves, 2013). 
However, its mechanism and role in tendon healing 
are yet unknown. Since tendons are hypovascular, in 
the long run, this can be a drawback for the healing 
process, where some vascularisation can provide 
extrinsic factors for a better healing (Barrientos et al., 
20 www.ecmjournal.org
O Evrova et al.                                                                                                     PDGF-BB delivery for tendon healing
Fig. 3. PDGF binding and signalling pathways. (A) PDGF-PDGFR interactions, where each unit of the 
PDGF dimer interacts with one receptor subunit. The interactions shown have been determined in vitro; 
weak interactions or conflicting reports are represented with dashed lines. (B) Signalling pathways after 
PDGF-BB binding and interactions with the cytoskeleton and integrins. Simplified representation of the 
main players and actions where many other elements and processes, especially feedback mechanisms, 
have been omitted (based on Andrae et al., 2008).
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2014; Fenwick et al., 2002). In this regard, application 
of PDGF-BB can prove beneficial, rather than VEGF, 
which has been shown to have deleterious effect 
on tendon healing, resulting in abundant hypoxia-
inducible factor 1 (HIF-1)/VEGF-induced and matrix 
metallopeptidase 3 (MMP-3)-supported angiogenesis 
with inferior biomechanical properties of the tendons 
(Sahin et al., 2012). The clinical efficacy of PDGF-BB 
(rhPDGF-BB) use in wound healing has been shown 
in several phase III studies, where its application is 
well tolerated and safe (Smiell et al., 1999).
Part A: Effects of PDGF-BB delivery in vitro
Need for controlled and sustained release of PDGF-
BB
Considering the healing process of acutely injured 
tendons, the correct timing of PDGF-BB administration 
is critical in determining the effectiveness of the 
growth factor therapy. Moreover, how PDGF-BB is 
delivered plays a role in whether the growth factor 
will be cleared right after administration or not. While 
PDGF-BB is ineffective when it is applied directly 
after injury [by injection (bolus)] or burst-released 
from a delivery device – which causes fast clearance 
of the growth actor at the wound site (Robinson and 
Talmadge, 2002) – a sustained release – allowing 
PDGF-BB presence at later time points, especially 7 d 
post-injury (Gulotta and Rodeo, 2009) – can lead to 
beneficial effects in terms of healing. Release refers 
to the process in which the molecule, i.e. growth 
factor of interest, migrates from the initial place 
within the polymeric system into the polymer’s outer 
surface and then to the release medium (example: 
wound site) (Langer, 1990). The release is a process 
that is affected by different factors, including the 
structural characteristics of the delivery system, 
the method used to incorporate the molecule into 
the delivery system, the release environment etc.. 
Optimally, a delivery device should have a release 
profile approaching zero-order kinetics, meaning 
that the release of the molecule of interest takes 
place at a constant rate, independent of the molecule 
concentration involved in the process (Fig. 4). A burst 
release is characterised by an initial large release of 
the molecule from the system (within hours or days) 
without further changes within time. However, a 
sustained release offers a release of the molecule from 
the system in a controlled manner, little by little, at 
every time point, without having a large decrease 
in the rate of release. Most of the sustained release 
delivery devices result, at best, in first-order release 
kinetics. This can fit well in the case of PDGF-BB 
delivery device, where its presence would be desired 
7 d post-injury, with a subsequent decrease and 
disappearance to avoid hypercellularity at the repair 
site. So far, several approaches have been tested for 
its delivery, which include heparin-based PDGF-BB 
immobilisation within different delivery devices 
or incorporation within polymeric scaffolds using 
different electrospinning techniques.
Heparin-based strategies for sustained PDGF-BB 
delivery
Heparin is a highly sulphated glycosaminoglycan, 
possessing moderate or strong binding affinity 
for several growth factors, including PDGF, FGF, 
TGFβ and VEGF (Guan et al., 2004; Lyon et al., 1997; 
Mangrulkar et al., 1995). Investigated primarily 
with a focus to reduce thrombogenicity of materials 
in contact with blood, its use also spread to the 
development of drug delivery constructs. Through 
electrostatic interactions, the negatively-charged 
heparin molecules bind positively-charged growth 
factors, such as PDGF-BB, preventing quick diffusion 
Fig. 4. Illustration of different 
molecules release profiles from 
polymeric delivery devices. Burst 
release is not desired, since almost 
the entire molecule of interest is 
released at once and very little or 
nothing is released in the subsequent 
time. Sustained release, which offers 
a more controllable rate of release, 
little by little, without having a big 
decrease in the rate of release is 
desired for most delivery devices and 
in the best case they approach first-
order release kinetics. Zero-order 
kinetics allows for a constant rate of 
release of the molecule, independent 
on molecule concentration.
22 www.ecmjournal.org
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and retaining their bioactivity with protection 
from heat, pH and enzymatic degradation (Guan 
et al., 2004). Heparin-based approaches for loading 
growth factors into constructs for tissue engineering 
applications have been used for different delivery 
systems including fibrin-based matrix (Thomopoulos 
et al., 2007) and electrospun polymeric fibres (Lee et 
al., 2012b).
Heparin-conjugated systems
These approaches utilise covalent immobilisation of 
heparin onto biomaterials by covalently binding it to 
proteins, such as collagen or albumin, using 1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide (EDC)/N-
hydroxysuccinimide (NHS) chemistry (Hennink et 
al., 1983; Wissink et al., 2000; Wissink et al., 2001). 
A demineralised bone matrix has been successfully 
crosslinked with heparin and loaded with PDGF-BB 
allowing for its sustained delivery and bioactivity 
retention (Sun et al., 2009). Heparin conjugation 
with electrospun polymeric fibres with subsequent 
PDGF-BB loading (Fig. 5A) has been done in only a 
few studies using poly (ε-caprolactone) (PCL)/gelatin 
fibres (Lee et al., 2012b), poly(L-lactide) fibres (plasma 
assisted heparin conjugation) (Cheng et al., 2014) 
and PCL/gelatin electrospun fibres (Lee et al., 2012a; 
Lee et al., 2012b), where cellular bioactivity and cell 
infiltration were studied.
Fibrin-based delivery devices
The fibrin-based delivery system with heparin-
immobilised PDGF-BB is the only one that has 
been explored for tendon regeneration application 
(Sakiyama-Elbert and Hubbell, 2000a; Sakiyama-
Elbert and Hubbell, 2000b; Thomopoulos et al., 
2007). This delivery system is based on a bi-domain 
peptide that includes a factor XIIIa substrate, derived 
from α2-plasmin inhibitor, at the N-terminus and a 
heparin-binding domain at the C-terminus. During 
coagulation, the bi-domain peptide is covalently 
crosslinked to the fibrin matrix by factor XIIIa. 
Heparin is immobilised electrostatically at the 
C-terminus and PDGF-BB is subsequently bound to 
heparin (Fig. 5B). In this system, compared to other 
heparin-based delivery systems, where heparin is 
covalently bound to the delivery construct, a non-
covalent immobilisation is performed using primarily 
electrostatic interactions with the heparin-binding 
peptide. The release of PDGF-BB from the matrix can 
occur by dissociation from the matrix-bound heparin 
and subsequent diffusion, proteolytic degradation of 
the fibrin matrix and/or enzymatic degradation of 
heparin (Gelberman et al., 2007).
Electrospinning – another approach for producing 
bioactive scaffolds delivering PDGF-BB
Electrospinning allows for production of scaffolds 
from different natural and synthetic polymers, fibrous 
and porous in structure, resembling the extracellular 
matrix (Rim et al., 2013). Further modifications of the 
chemical, biological and mechanical properties of the 
scaffolds allow for advancements in applications. 
Methods for incorporation of bioactive molecules, 
like growth factors, within electrospun scaffolds, 
include physical adsorption (Kovacevic et al., 2015) 
of biomolecules onto scaffolds, blend electrospinning, 
emulsion electrospinning and coaxial electrospinning 
(Fig. 6). While physical adsorption and blend 
electrospinning often result in burst release and can 
also cause growth factor denaturation, emulsion 
Fig. 5. Scheme of heparin-based delivery strategies for PDGF from different delivery matrices. (A) Scheme 
of heparin-conjugated electrospun PCL/gelatin fibres as a delivery device. The binding of PDGF-BB 
takes place in two steps. First, heparin is bound to the PCL/gelatin fibres through the formation of amide 
bonds, using EDC/NHS chemistry for activation of the carboxyl groups of heparin. Next, incubation 
with aqueous PDGF-BB allowed its immobilisation through electrostatic interactions with the heparin 
molecule. (B) Scheme of fibrin-based delivery system. During coagulation, a bi-domain peptide is 
covalently crosslinked to the fibrin matrix by factor XIIIa. Heparin is immobilised electrostatically at 
the C-terminus and PDGF-BB bound to heparin through electrostatic interactions is also immobilised 
within the carrier (Lee et al., 2012a; Lee et al., 2012b; Thomopoulos et al., 2007).
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and coaxial electrospinning are more promising 
approaches for a sustained PDGF-BB delivery.
In vitro sustained PDGF-BB delivery leads to 
similar biological responses to media supplemented 
PDGF-BB
Several characterisation studies throughout the years 
have been performed to determine the effects of PDGF-
BB on tenocytes or tenoblasts in in vitro conditions, 
while its effects on tendon progenitor stem cells have 
not yet been tested. One of the main responses upon 
addition of PDGF-BB in a dose-dependent manner, 
either in serum free or complete culture medium, is 
the increase in proliferation of tenocytes (Table 1) 
(Banes et al., 1995; Caliari and Harley, 2011; Costa 
et al., 2006; Evrova et al., 2016; Thomopoulos et al., 
2005; Wong et al., 2003). Typically, the increase in cell 
proliferation has been assessed by metabolic activity 
assays or DNA synthesis quantification assays, while 
not exploring which pathway exactly led to the 
observed response. Maintaining tenocyte phenotype, 
while accelerating cell proliferation in the initial 
reparative phase, would be useful for aiding the 
initial tendon healing. Increase in collagen synthesis 
upon PDGF-BB addition has also been observed in 
a concentration-dependent manner, where the effect 
plateaued at a concentration of 20 ng/mL, which could 
be due to saturation of available cell receptors for 
certain growth factor (Costa et al., 2006; Yoshikawa 
and Abrahamsson, 2001). Typically, 5-100 ng/mL 
PDGF-BB have been used as supplementation in in 
vitro experiments (Table 1), offering only an idea for 
the dosage that might be used in delivery devices or 
experiments in vivo.
 Using the heparin-conjugation system, a 
demineralised bone matrix, as well as electrospun 
polymeric fibres successfully crosslinked with 
heparin and subsequently loaded with PDGF-BB, 
Fig. 6. Schematic overview of different electrospinning methods for growth factor (GF) incorporation 
within polymeric scaffolds. (A) Single electrospinning allows for standard polymeric fibres to be obtained 
from a polymer solution where afterwards growth factors (GFs) can be physically adsorbed onto. (B) Blend 
electrospinning allows GF incorporation into the polymeric fibres by simply dispersing the GF directly 
into the polymer solution and electrospinning this mix. However, this is not a preferred method, since 
biomolecules can be damaged/denatured by the presence of organic solvents in the polymer solution. 
Usually delivery devices obtained with this method exhibit a burst release of biomolecules from the fibres. 
(C) Emulsion electrospinning allows for GF incorporation initially in an aqueous solution, which forms 
the aqueous phase of the water-in-oil (w/o) emulsion, where the polymer solution is the oil phase. This 
method allows for better protection of the GF in the presence of organic solvents and results in devices 
with a burst or a sustained release profile. (D) Coaxial electrospinning allows core-shell formation within 
the polymeric fibres, where the aqueous phase, carrying the GF of interest, constitutes the core within 
the fibres. Being in the aqueous phase, the GF are protected within the polymer shell and usually their 
release is in a sustained manner, rather than a burst release, governed by GF diffusion from the core and 
pore formation within the polymer shell.
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Table 1. Summary of in vitro tested conditions and cellular responses upon PDGF-BB administration.
In vitro model
PDGF 
concentration Administration Time point Cellular response
Avian flexor tendon 
epitenon cells; internal 
fibroblasts (tenocytes) 
(P2–P4) (Banes et al., 
1995)
10, 50, 100 pM
Supplemented in 
serum free culture 
medium-1d
1 d
DNA synthesis ↑ in a 
dose-dependent manner 
in both cell populations. 
Mechanical stimulation 
had synergistic role on 
DNA synthesis
Canine intrasynovial 
flexor tendon 
fibroblasts (P2+) 
(Thomopoulos et al., 
2005)
10 ng/mL 
or 2-100 ng/
mL in 
combination 
with bFGF
Supplemented in 
serum-free culture 
medium
1 d
Cell proliferation ↑  
Total collagen synthesis ↑
Synergistic effect together 
with bFGF (within 5-40 ng/
mL for DNA synthesis and 
5-20 ng/mL for collagen 
synthesis)
Rabbit flexor tendon 
(synovial sheath, 
epitenon and 
endotenon) tenocytes 
(P4 or less) (Costa et al., 
2006)
1, 10 or 50 ng/
mL
Supplemented in 
serum-free culture 
medium
3 d Cell proliferation ↑ in a dose-dependent manner
Equine digital flexor 
tenocytes (P2-3) 
(Caliari and Harley, 
2011)
10, 50 or 
100 ng/mL
Supplemented in se-
rum-free culture me-
dium with tenocytes 
seeded on collagen-
GAG scaffolds
1 d, 4 d, 7 d Cell proliferation ↑  Cell metabolic activity ↑
Equine digital flexor 
tenocytes (P4) (Caliari 
et al., 2014)
100 ng/mL
Supplemented in 
serum+ culture 
medium
1 d 
 
Tenocyte migration 
through collagen-GAG 
scaffold ↑
Rabbit Achilles tendon 
tenocytes (P1-P4) 
(Evrova et al., 2016)
1-50 ng/mL 
or delivered 
by emulsion 
electrospun 
scaffolds
Supplemented in 
serum+ and serum-
free medium; PDGF-
BB delivered from 
bioactive scaffolds
1 d, 3 d, 
7 d, 14 d
1 d
Cell proliferation ↑ (serum 
free conditions); this effect 
was not significant in 
serum conditions.
Cell proliferation of 
tenocytes on bioactive 
scaffolds ↑
Human patellar 
tendon tenocytes  
(P2-P4) (Wong et al., 
2003)
10 ng/mL
Supplemented 
in serum culture 
medium
2 d
PDGF-BB reversed the 
effects of dexamethasone 
which led to cell viability/
proliferation ↓and collagen 
synthesis ↓
Human hamstring 
tenocytes (P3) (Qiu et 
al., 2014)
5, 10, 50 ng/
mL
Supplemented in 
serum-free culture 
medium
1 d, 7 d, 
14 d
Cell proliferation ↑  
Slight total collagen ↑ 
Tenomodulin, scleraxis, 
decorin expression ↓
Rabbit intrasynovial 
flexor tendon and 
extrasynovial peroneal 
tendon explants 
(Yoshikawa and 
Abrahamsson, 2001)
0.1-100 ng/mL
Supplemented in 
serum-free culture 
medium
4 d
Proteoglycan synthesis, 
collagen synthesis and cell 
proliferation ↑
Equine superficial 
digital flexor tendon 
explants (Haupt et al., 
2006)
1, 10, 50 or 
100 ng/mL
Supplemented in 
culture medium with 
reduced serum (2 %)
6 d
Type I collagen gene 
expression ↑ 
Cell proliferation, GAG 
and total collagen content 
– n.a.
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have been shown to successfully retain PDGF-
BB bioactivity and allow for sustained delivery, 
compared to physically adsorbed PDGF-BB. The 
same delivery devices, with physically adsorbed 
PDGF-BB, exhibited a burst release of the growth 
factor within the first 3-4 d (Lee et al., 2012a; Sun et 
al., 2009).
 Studies on tendon explants have shown 
results similar to cell cultures. Stimulated cell 
proliferation and collagen synthesis, upon PDGF-
BB supplementation in the culture medium, were 
observed in intermediate and proximal intrasynovial 
flexor and extrasynovial peroneal tendon segments 
(Yoshikawa and Abrahamsson, 2001). On the other 
hand, Haupt et al. (2006), in a study on equine tendon 
explant, reported different results regarding the 
effect of PDGF-BB. No changes in morphology of 
the tendons, nor proliferative changes were detected 
upon addition of different concentrations of PDGF-
BB. High concentrations led to increase in collagen 
type I gene expression and decrease in collagen 
type III gene expression, with no changes in the 
glycosaminoglycan content.
 PDGF-BB was also shown to play a role in the 
regulation of different integrin receptors, namely 
alpha(v)beta3 and alpha5beta1 receptors. These 
specific integrins can be important in intrasynovial 
flexor tendon healing, since alpha5beta1 is involved 
in fibronectin deposition, as part of the provisional 
formed matrix. ECM remodelling might play a 
role in mechanotransduction (Regent et al., 2011), 
while alpha(v)beta3 is involved in angiogenesis/
revascularisation (Brooks et al., 1994; Hodivala-
Dilke, 2008). Semi-quantitative reverse transcription 
PCR showed that PDGF-BB increased expression of 
alpha(v) mRNA 3-fold, whereas alpha5 expression 
was increased 2-fold in intrasynovial flexor tendon 
cells (Harwood et al., 1999).However, not much is 
known about  effect of PDGF-BB on tendon specific 
markers, such as Scx or tenomodulin. Qiu et al. (2014), 
exploring different growth factor combinations for 
serum-free tenocyte expansion, observed a decrease 
in Scx, tenomodulin and decorin gene expression 
after 14 d, upon PDGF-BB supplementation. 
Tenocytes, cultured for 14 d in 50 ng/mL of PDGF, 
showed a similar expansion trend compared to 
tenocytes cultured in 10 % FBS (control group) and 
a slight increase in total collagen content and gene 
expression of type I collagen. Younesi et al. (2016) 
showed a decrease in Scx, tenomodulin and type I 
collagen gene expression in tenocytes cultured on 
collagen threads with immobilised PDGF-BB, in 
comparison to collagen threads only, but an increase 
in gene expression when compared to collagen gels.
 Similar to media-supplemented PDGF-BB, 
different studies have addressed the bioactivity of 
PDGF-BB after being delivered by the system. These 
studies have assessed the effect of PDGF-BB on cell 
proliferation, i.e. increase in DNA content (Table 2).
 So far, the most widely characterised delivery 
device for in vitro conditions has been a fibrin-
based delivery system that allows immobilisation 
of heparin-binding growth factors, such as PDGF-
BB, thus protecting them from degradation prior to 
release at the tendon injury site (Sakiyama-Elbert and 
Hubbell, 2000a; Sakiyama-Elbert et al., 2008) (Table 
2). This system, allowing for a sustained PDGF-
BB delivery over a period of 10 d, has significant 
advantages compared to the bolus application of 
growth factors (growth factors are cleared within 
48 h) (Robinson and Talmadge, 2002) or traditional 
synthetic polymeric delivery systems that can create 
acidic environment during degradation (Zisch et 
al., 2003). Tested in vitro on canine tenocytes, fibrin 
matrices with PDGF-BB led to a significant increase in 
total DNA, compared to martices without PDGF-BB 
or matrices with PDGF-BB but without the delivery 
system. After 6 d in culture, collagen synthesis was 
enhanced to a greater extent by controlled delivery of 
PDGF-BB, rather than by PDGF-BB in fibrin matrices 
without delivery system, suggesting a need for its 
sustained delivery over time (Sakiyama-Elbert et 
al., 2008). In a subsequent study, sustained delivery 
of PDGF-BB from the fibrin system resulted in 
downregulation of collagen (Col I and Col III) and 
lubrican gene expression at day 5. This suggests that 
downregulation of collagen genes by PDGF-BB may 
not necessarily translate into decreased production 
of collagen or that specific post-transcriptional 
events can play a role (Thomopoulos et al., 2010a). 
Additionally, it has been suggested that PDGF-
BB does not directly affect collagen synthesis, but 
rather that it is a potent chemoattractant for wound 
macrophages and fibroblasts, which may stimulate 
endogenous increase in TGFβ and, in turn, stimulate 
new collagen synthesis and enhancement in wound 
healing (Pierce et al., 1989).
 Due to the fact that the solely fibrin-based delivery 
system might not provide a surgically manageable 
construct for tendon repair, Manning et al. (2013) 
improved its structural integrity by layering it with 
an electrospun poly(lactic acid-co-glycolic acid) 
(PLGA) backbone and incorporating adipose-derived 
mesenchymal stem cells into the fibrin-based delivery 
system. The bioactivity of the delivered PDGF-BB was 
not directly assessed but, over a period of 14 d, the 
cell viability within the scaffolds was not affected.
 Another delivery device tested for tendon healing 
application was an emulsion electrospun DegraPol® 
scaffold with incorporated PDGF-BB. When assessed 
in vitro, tenocytes showed increased proliferation as a 
result of released PDGF-BB in serum-free conditions 
or when directly seeded on bioactive scaffolds in 
serum conditions, thus showing PDGF-BB retained 
its bioactivity during the electrospinning process 
(Evrova et al., 2016).
 PDGF-BB delivery has been tested for other 
applications as well, where different delivery 
strategies were used (summarised in Table 2). In most 
studies, testing the bioactivity of incorporated and 
released PDGF-BB was done by looking at increase in 
cell proliferation, as the most pronounced biological 
26 www.ecmjournal.org
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outcome after PDGF-BB supplementation (Table 
2). Significant increase in cell proliferation upon 
PDGF-BB delivery, using different systems, was 
usually observed after 4 or 7 d, similar to PDGF-BB 
supplemented directly in the culture medium (Table 
1). When DNA synthesis was studied, a short time 
point of 24 h was used for the delivery devices or 
media supplementation and a significant increase 
in DNA synthesis after PDGF-BB stimulation 
was observed in both cases (Table 1,2). However, 
besides the well-established proliferative effects, 
more systematic studies on the effect of PDGF-BB 
on some of the tendon specific markers in tenocytes 
and tendon stem cells are needed in order to obtain 
more conclusive insight about its possible impact in 
tendon healing.
 The loaded amounts of PDGF into the delivery 
devices explored (Table 2) are generally larger 
than the amounts supplemented directly in culture 
medium (Table 1). However, usually 100 % loading 
efficiency within the device is not achieved and 
beside the sustained delivery they offer, still in some 
systems, under in vitro conditions, large amounts of 
encapsulated PDGF-BB are not released. Taking this 
into account, the amount of released PDGF-BB over 
time could be smaller or comparable to the media 
supplemented one, which, on the other hand, can 
drastically differ once the delivery device is used in 
in vivo conditions.
PDGF-BB delivery device design: easy handling, 
surgery compatibility and sustained release kinetics 
are important for successful application in tendon 
repair
Most strategies explored for PDGF-BB delivery 
experienced a sustained release of PDGF-BB over 
a period of several days (Table 2). A sustained 
release of growth factor was achieved using heparin 
immobilisation on PCL/gelatine scaffolds, where 
physical adsorption of PDGF-BB on the scaffolds 
resulted in a burst release within the first 3-4 d (Lee 
et al., 2012b).
 The release kinetics of PDGF-BB from the fibrin-
matrix-based delivery system can be modulated 
by different molar ratios of PDGF-BB to heparin, 
different amounts of PDGF-BB loading and also 
different gel size (Sakiyama-Elbert et al., 2008). 
In in vitro conditions, decreasing the molar ratio 
of PDGF-BB to heparin, from 1 : 10 to 1 : 10,000, 
led to significantly more sustained delivery of 
PDGF-BB within 10 d (Sakiyama-Elbert et al., 2008; 
Thomopoulos et al., 2007). Three different doses of 
PDGF-BB loading were evaluated (0.125, 0.25 and 
1.25 μg/mL), where increase in the amount loaded led 
to more sustained release. Varying the fibrin matrix 
size did not have a major effect on the release rate 
of PDGF-BB and its passive release should correlate 
between different matrix volumes (Sakiyama-Elbert 
et al., 2008). The release of PDGF-BB from the fibrin-
based matrices was tested in the presence of cells and 
it was observed that its release is in a dose-dependent 
manner and similar to the in vitro passive release 
(Sakiyama-Elbert et al., 2008).
 The explored electrospun scaffolds, produced with 
either emulsion or coaxial electrospinning, also allow 
for sustained PDGF-BB delivery (Table 2). PDGF-
BB has been incorporated within PCL and PCL/
poly(ethylene oxide) (PEO) electrospun scaffolds, 
intended for bone tissue engineering applications 
(Briggs and Arinzeh, 2013; Briggs et al., 2015). These 
types of scaffolds allow for sustained delivery of 
PDGF-BB over a period of 4 d, but without complete 
release of the growth factor from the polymeric 
scaffolds, while a fraction of it is likely to be bound 
to the scaffold in a bioactive form (Briggs et al., 2015). 
Recently, DegraPol®, an elastic polyester urethane, 
block copolymer, has been studied as a delivery 
device for PDGF-BB. It allowed for the successful 
incorporation and sustained release of PDGF-BB 
within a period of 30 d. However, similar to the PCL 
and PCL/PEO scaffolds, a large amount of growth 
factor was still inside the scaffold or strongly bound to 
the surface and, therefore, not released (Evrova et al., 
2016). PDGF-BB has been successfully incorporated 
in the core of PCL and PCL/polyethylene glycol 
(PEG) fibres (Liao et al., 2006). Incorporation of PEG 
in the PCL shell through blending, rendered the 
fibres permeable to protein by inducing swelling 
and pore formation. The release kinetics could be 
controlled by varying the nature and amount of PEG 
in the shell of the nanofibres. Absence of PEG in the 
shell layer resulted in negligible release of PDGF-BB 
since PDGF-BB itself cannot generate open pores 
throughout the shell layer. A very small amount is 
in the core of the fibres and the diffusion through the 
bulk PCL shell could be too slow to take place in the 
desired time frame (Jiang et al., 2014). In the different 
scaffolds tested, PDGF-BB exhibited sustained 
release profile over 35 d and it was shown to be 
bioactive (Liao et al., 2006). Li and co-workers have 
produced dextran (DEX)/poly(L-lactide-co-epsilon-
caprolactone) (PLCL) coaxially electrospun fibres 
carrying PDGF-BB. In their studies, the electrospun 
scaffolds showed a burst release of PDGF-BB in the 
first 2 d, followed by a steadier release up to 28 d (Li 
et al., 2010).
 So far, for tendon repair applications, coaxial 
electrospun scaffolds have not been utilised for 
delivery of PDGF, neither in vitro nor in vivo, while 
emulsion electrospun scaffolds have been explored 
in vitro. These techniques might offer an advantage 
over the heparin-based delivery systems. One 
disadvantage of the heparin-based delivery systems 
lie in the preparation step. The conjugation of heparin 
to the polymeric scaffold requires the immersion 
and incubation of the device with all the necessary 
solutions, including the heparin solution, and in 
the next step the incubation with PDGF solution. 
This process allows for complete conjugation of 
the scaffold with heparin and subsequently PDGF. 
However, once applied at the tendon injury site, 
PDGF delivery is desired preferably towards the 
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tendon and not the surrounding tissue, where its 
diffusion can affect neighbouring cells and lead to 
undesired side effects, such as adhesion formation 
(Meier Buergisser et al., 2014; Meier Buergisser and 
Buschmann, 2015). Because of this, layered scaffolds 
could be considered as an alternative, which might 
allow for more spatial selection for PDGF delivery 
primarily towards the tendon tissue.
 Using electrospinning techniques, a physical 
separation between the bioactive layer of the scaffold 
and the surrounding tissue of a tendon can be 
achieved, with a directed, localised delivery of PDGF-
BB. Recently, this approach was associated with the 
use of a double-layered DegraPol® tube that has a 
bioactive and non-bioactive layer, to be applied over 
ruptured and conventionally sutured tendon in order 
to promote tendon healing with PDGF-BB delivery 
(Evrova et al., 2016).
PART B: Effects of PDGF-BB delivery in vivo
Impacts of PDGF-BB
Although in vitro release studies are necessary for 
the characterisation of a delivery device, in vivo 
experiments and assessments are absolutely needed 
to discover its real effects in the field of tendon injuries 
or any other application explored. The problem often 
confronted is that in vitro release kinetics may differ 
from in vivo release kinetics, once the delivery device 
comes in contact with tissues and body fluids, where 
it is exposed to additional degradation by enzymes. 
Enzymes that are present at inflamed wound sites 
and found in plasma, by oxidation or hydrolysis, 
can affect the degradation rate of the material 
and, thus, influence the release profile from the 
device. Also, sterilisation methods, as part of in vivo 
procedures and regulations can affect the material 
degradation (Savaris et al., 2016) and bioactivity of 
the incorporated growth factors (Mainil-Varlet et al., 
1997; Moioli et al., 2006). Furthermore, the stability 
and bioactivity of the released growth factor at the 
wound site can differ from the in vitro conditions.
Fibrin-based delivery device
In vitro, PDGF-BB has been shown to support 
proliferation and DNA synthesis, as described in 
detail in part A. Hence, accelerated wound healing 
is expected in vivo, which has been confirmed for 
a fibrin-based system. Moreover, PDGF-BB was 
shown to improve the gliding capacity, an aspect 
that can only be confirmed by in vivo experiments. 
This fibrin-based delivery system, where PDGF-BB 
is attached to heparin, which is itself electrostatically 
bound to a peptide acting as a bridge to fibrin (Fig. 
5B) (Sakiyama-Elbert et al., 2008), was tested in a 
canine flexor tendon model (Thomopoulos et al., 
2007) (Table 3). The intrasynovial flexor tendons of 
the forepaw were fully and transversely transected, 
sutured with an 8-strand suture and the defect was 
filled with the gel, acting as a delivery system. 100 ng 
of PDGF-BB were incorporated into the delivery 
device and tendons were analysed histologically 7 
and 14 d postoperatively. Cell density, proliferation, 
total DNA levels, reducible collagen crosslink levels 
and type I collagen expression were assessed. A 
clear beneficial effect was observed in comparison 
to the control group, where the dogs received the 
same transection, pocketing and suture without 
fibrin gel application. Cell density, proliferation 
and type I collagen expression were increased in 
PDGF-BB-treated specimens at both time points, 
compared to the control. Also, reducible collagen 
crosslinks were significantly increased 7 d post-
operatively, which indicates that the PDGF-BB-
treated tendons demonstrated accelerated healing; 
reducible crosslinks increased when the remodelling 
phase was entered. In contrast to these positively 
influenced parameters, the collagen organisation 
and the inflammatory reaction were similar in both 
groups, thus not affected by PDGF-BB. Moreover, 
with an increased dosage of 500 ng of PDGF-BB, 
incorporated in the same delivery system, and 
increase in cell density, proliferation and type I 
collagen expression were detected 14 d post-operation 
and confirmed previous results (Thomopoulos et al., 
2009).
 This fibrin-based PDGF-BB delivery system was 
also evaluated 3 weeks post-surgery, in terms of 
gliding capacity (range of motion) and biomechanical 
strength (Gelberman et al., 2007). Interestingly, PDGF-
BB-treated specimen exhibited a higher range of 
motion. The rotations of the proximal interphalangeal 
(PIP) joint and the distal interphalangeal (DIP) joint 
were assessed, based on the differences between 
the flexed and extended positions. The DIP and 
PIP ranges of motion (ROMs) were significantly 
higher in the PDGF-BB group (around doubled 
ROMs). Besides its mitogenic effects, there is some 
evidence that PDGF-BB stimulates the biosynthesis 
of hyaluronan, one of the most studied and applied 
anti-adhesives (Meier Buergisser and Buschmann, 
2015) and an important lubricant of the intrasynovial 
fluid in healthy tendons. Biosynthesis of hyaluronan, 
as a result of PDGF-BB application, has been reported 
for tenocytes (Thomopoulos et al., 2009), as well 
as for prostate smooth muscle cells (Pullen et al., 
2001), cardiomyocytes (Hellman et al., 2010) and 
temporomandibular joint disc-derived cells (Hanaoka 
et al., 2006). The application at the wound site of 
a sustainable, releasing, PDGF-BB-loaded device, 
not only accelerated wound healing 1 and 2 weeks 
post-surgery (Thomopoulos et al., 2007), but also 
enhanced significantly the gliding of the tendons, 
as found 3 weeks post-intervention (Gelberman et 
al., 2007). In a subsequent study, where PDGF-BB 
amount was increased five-fold (to 500 ng) and the 
time point of tendons extraction was increased to 6 
weeks, Thomopolous and co-workers confirmed the 
higher range of motion in the PDGF group, compared 
to control (Thomopoulos et al., 2009). Moreover, the 
increase in hyaluronic acid in PDGF group, compared 
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to control, supported one of the authors’ hypotheses, 
namely that PDGF-BB stimulated the production of 
hyaluronic acid (Thomopoulos et al., 2009).
 Although the fibrin-based delivery device 
(Sakiyama-Elbert et al., 2008) had been shown 
to promote tendon healing (Thomopoulos et al., 
2007) and gliding capability, it did not enhance the 
biomechanical properties 3 weeks post-surgery, with 
peak forces, stiffness and strain at 20 N being very 
similar for PDGF-BB group and control group. The 
authors attributed this ineffectiveness to PDGF-BB 
dosage – the gel had been loaded with only 100 ng 
of PDGF-BB (Gelberman et al., 2007). In a later 
study, although the loading amount of PDGF-BB 
in the fibrin-based matrix was increased to 500 ng 
and the time point of post-operative examination 
extended to 6 weeks, the biomechanical properties 
were still similar with and without PDGF-BB delivery 
(Thomopoulos et al., 2009). Even though the sustained 
release of PDGF-BB from the corresponding matrix 
was detected in vitro over 10 d (Thomopoulos et al., 
2007), in vivo conditions may differ in many aspects 
from in vitro conditions, affecting fibrin degradation, 
as well as, PDGF-BB release kinetics and stability at 
the wound site. Hence, promising findings in vitro 
have ultimately to be confirmed in vivo.
Delivery device in combination with stem cells
Although the fibrin-based system with PDGF-BB 
attached to heparin (Sakiyama-Elbert et al., 2008) 
allowed for an enhanced flexor tendon healing 
(Thomopoulos et al., 2007; Thomopoulos et al., 2009), 
the handling of the hydrogel, with its soft consistency, 
was difficult during surgical implantation. To 
overcome the rather difficult consistency, the 
hydrogel was layered with electrospun PLGA fibre 
meshes. A second potential improvement was the 
simultaneous seeding of adipose-derived stem cells 
(ASCs) (Manning et al., 2013). An alternating layered 
scaffold was constructed with PDGF-BB and ASCs 
incorporated in the heparin-fibrin delivery layers 
and with layers made of PLGA (no PDGF-BB, no 
cells). After a full transection of canine flexor tendons, 
longitudinally-oriented horizontal slits were created 
in the centre of each tendon stump and the layered 
scaffold was implanted and fixed by suture at the 
repair site. It was reported that the release of PDGF-
BB in vitro was 22 % on the first day and progressed 
steadily to 71 % by day 9. In addition, in vivo, at the 
repair site, the fluorescently-labelled cells were still 
viable after 9 d. Although the presence of ASCs might 
further enhance the flexor tendon healing, the layered 
scaffold was also implanted with PDGF-BB alone, 
incorporated in the fibrin-based layers (no ACSs). 
In terms of cellular response during early healing, 
it was found that the cellularity and vascularity in 
the cell-free scaffold with PDGF-BB were slightly 
decreased at day 9 post-operation, when compared 
to the repair-only group (only suture). In contrast, 
inflammatory cells, such as foreign body giant cells, 
poly-morphonuclear cells and monocytes, were 
slightly increased in the acellular PDGF-BB system 
(Manning et al., 2013), suggesting a mild immune 
response towards the scaffold material (PLGA). 
Hence, although acceleration of cell proliferation by 
PDGF-BB has been shown to be manifold in vitro, this 
example shows that total cell densities during the 
healing process change with time and, at certain time 
points after injury, may be decreased, compared to 
native densities – which is impossible to demonstrate 
in vitro. Moreover, , in vivo, at the repair site, the 
impact of PDGF-BB on inflammatory cells and the 
relative abundance of macrophages, monocytes, 
foreign body giant cells may differ from single cell 
cultures,, where the chemotactic effect of PDGF-BB 
on macrophages  (Inaba et al., 1993), monocytes and 
neutrophils (Deuel et al., 1982) can be observed with 
a single focus on these cell types – regardless of the 
multiple orchestra of factors and cytokines released 
from all cell types present at the wound site. Again, 
we conclude that in vivo experiments are absolutely 
necessary to elucidate the mentioned issues.
Single bolus injection
As different enzymes may affect the stability and 
bioactivity of PDGF-BB in vivo, the outcomes for 
dosage’s effect must be examined concisely. In a 
rat Achilles tendon model, it has been shown that 
lower dosages may positively affect biomechanical 
outcomes äat early time points, i.e. one week post-
operation, while higher dosages have this effect 
only at later time points, i.e. 3 weeks. In this rat 
Achilles tendon model, tendinopathy was induced 
by collagenase, 7 d prior to PDGF-BB administration. 
When the healing tissue was analysed histologically 
for cellularity, collagen fibre orientation and density, 
inflammation and vascularisation, it was found that 
different amounts of single bolus applied at the 
wound site had different dose-dependent effects. 
Furthermore,  biomechanical strength, 1 and 3 weeks 
post-administration, was also influenced by PDGF-BB 
(Shah et al., 2013).
 When doses of 1.02, 10.2 and 102 μg of PDGF 
were applied, the cell proliferation was significantly 
increased at 10.2 and 102 μg, but not at 1.02 μg of 
PDGF. 3 weeks post-application, inflammatory 
reaction and vascularisation were significantly 
increased only at the highest dose (102 μg of PDGF). 
Furthermore, assessment of biomechanics revealed 
that only the highest dose group had significantly 
larger failure loads at 1 and 3 weeks, compared to 
the other treated groups – indicating a biphasic dose-
dependence and the need for an exact evaluation of 
the optimum growth factor amount (Shah et al., 2013).
 Solchaga et al. (2014) also worked with a single 
injection of PDGF-BB. Either 3 or 10 μg of PDGF-BB, 
dissolved in 30 µL of PBS, were intra-tendon injected in 
a rat Achilles tendon model, where the tendinopathy 
was induced by collagenase. The proliferating 
cells were quantified in a histological section by 
proliferating cell nuclear antigen (PCNA) positive 
cell counting. It was found that cell proliferation was 
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significantly increased, with 65 % more proliferating 
cells, in the 10 µg of PDGF-BB-group, compared to 
saline control. In terms of inflammatory reaction, no 
different effect was detected for both doses, when 
compared to the control.
 In this tendinopathy model, biomechanical 
properties of the tendons were positively influenced 1 
and 3 weeks post-administration and only at 10.2 μg 
of PDGF. Other concentrations have not shown 
a significant difference compared to the normal 
untreated control (Shah et al., 2013). On the other 
hand, ultimate tensile stress was only significantly 
higher, compared to the other groups, in the 1.02 μg 
of PDGF group. Such findings stress the importance 
of an appropriate dosage, which can be easily and 
exactly chosen when single bolus injections are used, 
but is a more delicate and difficult issue when growth 
factor delivery devices are used to release the factor 
in a controlled way. The beneficial effects in terms 
of biomechanics were reported also for a rat Achilles 
tendon tendinopathy model, where 3 or 10 µg of 
PDGF-BB were applied intra-tendon as a single 
injection (Solchaga et al., 2014). Analysis post-surgery 
revealed that the ultimate loads were increased by 
factor of 1.96 and 1.36 for the 3 µg group and 1.22 and 
1.92 for the 10 µg group all at 7 and 21 d post-surgery, 
respectively. Similarly, stiffness increased by factors 
of 1.58 and 1.09 for the 3 µg group and 1.03 and 2.00 
for the 10 µg group at 7 and 21 d, respectively. It may 
be concluded that smaller amounts of PDGF-BB, such 
as 3 µg, enhance biomechanics in the first week, while 
larger amounts of PDGF-BB, such as 10 µg, lead to 
better biomechanical outcomes only later (as shown 
here for 3 weeks) (Solchaga et al., 2014).
PDGF-BB adsorbed on collagen
In a rat rotator cuff model, PDGF-BB was applied 
in three different dosages using a commercial 
collagen I scaffold (BioBlanket Surgical Mesh; 
Kensey Nash, Exton, PA, USA). Either 0.6, 2 or 6 μg 
of PDGF-BB were dissolved in a sodium acetate 
buffer and small volumes of it were adsorbed 
on the scaffold immediately before surgical 
implantation (Kovacevic et al., 2015). Histological and 
biomechanical analyses were performed at 5 and 28 d, 
respectively. Cellular proliferation, detected with 
PCNA immunohistochemical analysis at day 5, was 
found to be dose-dependent, with the highest number 
of actively dividing cells at the highest dosage of 
PDGF-BB. The same was found for the angiogenic 
response: the strongest staining was detected for 
the highest dosage of PDGF-BB, when analysed 
with Factor VIII immunohistochemistry. However, 
proteoglycan staining and collagen birefringence, 
both analysed 28 d post-surgery, did not reveal any 
difference between the PDGF-dosage groups, nor 
between the groups and the control, where a collagen 
scaffold without PDGF-BB was implanted (Kovacevic 
et al., 2015).
 Although promising effects at the cellular level 
were found for this collagen delivery system, with 
PDGF-BB adsorbed in different dosages, no beneficial 
effect were observed 28 d post-operation on the 
biomechanical outcome, when the delivery system 
was applied as a rat supraspinatus augmentation 
(Kovacevic et al., 2015). No significant differences 
were measured in ultimate load and stiffness, when 
the scaffolds loaded with 0.6, 2.00 or 6 μg of PDGF-BB 
were compared to the pure scaffold.
Non-viral PDGF-BB gene transfer
S u r f a c e - m o d i f i e d  s i l i c a  n a n o p a r t i c l e s 
(functionalisation with amino- and subsequently 
carboxylic-functional groups) were used as a vehicle 
for pDNA plasmid encoding PDGF-B gene (Suwalski 
et al., 2010). In a rat Achilles tendon model, three 
longitudinal incisions were made and 50 µL of the 
pDNA/nanoparticle (2 : 5) were injected into the 
middle incision. 15 d post-treatment, biomechanical 
measurements revealed that the gene transfer using 
these nanoparticles improved the ultimate load, while 
the Young’s modulus was similar, when compared 
to the control. As silica may induce inflammatory 
reaction when used as an implant material (Lin et 
al., 2006), Suwalski and co-workers investigated this 
aspect as well. Histological analysis revealed no local 
inflammation nor necrosis, even when analysed after 
6 weeks (Suwalski et al., 2010).
 Another type of non-viral-based gene transfer 
vehicle, realised with liposomes, was developed and 
beneficially applied in a rat Achilles tendon model 
with triple longitudinal incisions used as tendon 
laceration. 50 µL of liposomes, of two different 
compositions, containing 20 μg of plasmids DNA 
encoding PDGF gene were slowly injected into the 
middle section of the Achilles tendon. 14 d post-
injection, the PDGF group showed a stiffness of 83 % 
compared to uninjured tendon, while the non-treated 
control only reached 72 %, indicating a beneficial in 
vivo effect at early time points during the healing 
process (Delalande et al., 2015).
PDGF-BB coated sutures
As an alternative to the delivery systems described 
above, Cummings et al. (2012) reported on a PDGF-
BB-coated Vicryl suture, applied in a rat Achilles 
tendon transection model. By dipping the sutures 
in either 0 (control), 0.3, 3 or 10 mg × mL-1 of PDGF 
solutions, the authors could show the beneficial 
effect, 4 weeks post-operatively, of PDGF-BB-coated 
suture. The biomechanical properties increased in 
a dose-dependent manner and improved tissue 
remodelling with decreased tendon cross-sectional 
area and improved collagen organisation in the 
repaired tendons.
Current limitations and future work
PDGF-BB is well known for its mitotic, chemotactic 
and angiogenic activity (Anitua et al., 2012) and 
because of this, it is considered as a promising 
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candidate for tendon repair. As it is FDA approved 
and used in clinical settings for other applications, 
no safety problems are expected to arise with its use 
for tendon repair (Paul et al., 2015; Solchaga et al., 
2012; Ziyadeh et al., 2011). Many in vitro studies with 
tenocytes clearly demonstrate its biological properties 
(Raghavan et al., 2012; Zhao and Hadjiargyrou, 2011), 
while studies of its effects on the tendon progenitor 
stem cell population are still missing. On the other 
hand, most studies explored cell responses in 2D 
environment, while this can differ in 3D models 
(Antoni et al., 2015; Pampaloni et al., 2007) and 
can help bridge the gap with in vivo experimental 
outcomes. Even though there are some observations, 
systematic information is still missing on how PDGF-
BB alone, or in interplay with other growth factors, 
could affect specific tendon markers (tenomodulin, 
Scx, Mohawk etc.).
 So far, in vitro experiments do not allow for 
direct correlations and conclusions when it comes 
to prediction of in vivo outcomes. In vivo models are 
necessary for determining its biological impact on 
biomechanical properties (Buschmann and Meier 
Buergisser, 2017) or tissue composition. Similarly, 
the effectiveness of any PDGF-BB delivery device, 
allowing for its sustained delivery over a longer 
period in in vitro conditions, accompanied with 
promising outcomes, can differ in vivo, potentially 
resulting in reduced effectiveness in aiding tendon 
repair. Two main parameters for in vivo effectiveness 
are dosage and time of application, which may be 
difficult to simulate in cell culture conditions or in 
three-dimensional cultures using tissue engineered 
constructs (Juncosa-Melvin et al., 2006). Low dosages 
(~ 100 ng) of PDGF-BB delivered in vivo in a sustained 
manner enhanced cell proliferation, but did not show 
any beneficial impact on biomechanics (Thomopoulos 
et al., 2007). Only higher doses (~ 500 ng) of PDGF-
BB delivered in the same way resulted in beneficial 
effects (Thomopoulos et al., 2009). On the other 
hand, when single bolus injections (Shah et al., 2013) 
or different scaffolds/carriers are used for delivery 
(Kovacevic et al., 2015), much larger amounts (1-
10 µg) might be needed to have any effect on the 
biomechanics of the tendons. With the current studies 
suggesting higher dosages of PDGF-BB as promising, 
a systematic study in one in vivo model, with different 
delivery methods and dosages and the possibility 
to track the release profile of the growth factor in 
vivo is missing. These types of studies would offer 
valuable insights into the mechanism of release and 
what really plays an important role in improving the 
resulting biomechanical properties.
 The proper time of application and delivery is the 
second important aspect that can affect the success 
of the biological therapy with PDGF-BB. Very early 
administration (immediate up to 3 d post-injury) in 
a single shot did not add any benefits to the healing 
process and might not be the correct approach. 
Ideally, PDGF-BB should be applied around 1 week 
post-laceration (Chan et al., 2006; Gulotta and Rodeo, 
2009) by a single bolus injection. Even better, it could 
be incorporated in a delivery system that allows its 
sustained release to the wound site over the duration 
of at least two weeks. Delivery systems that partially 
degrade during the first week post-operation, leading 
to largest release of PDGF-BB after this period, could 
be considered as promising candidates for tendon 
rupture repair. However, careful and comprehensive 
degradation and integration studies of the delivery 
device in vivo, without any growth, factor should 
be initially performed. For example, the polymer 
DegraPol®, intended to be used as a PDGF-BB delivery 
device for tendon repair (Evrova et al., 2016), has been 
thoroughly investigated for its in vivo effects in terms 
of cellular response prior to PDGF-BB incorporation 
(Buschmann et al., 2013; Buschmann et al., 2015). 
Moreover, there is little to no knowledge about the 
half-life of delivered PDGF-BB at the wound site from 
the different devices or its half-life within the different 
biomaterials and devices. This can be an important 
parameter to be determined for establishing the 
effectiveness of any proposed delivery strategy 
and needs future research. Future studies should 
focus on standardised animal models to enable the 
comparison of different delivery devices, at best 
implanted in the same way into the same animal 
model. Moreover, methods, readouts and time points 
of post-operative analysis should be standardised 
to allow for a full and adequate comparison of 
different delivery strategies, dosages used or time 
points tested. Only data resulting from comparable 
in vivo experiments could be used to elucidate which 
strategy might be best to be transferred into clinical 
trials later. Unfortunately, so far, different research 
groups have focused on selected aspects, such as only 
biomechanical readouts, only inflammation or tissue 
remodelling etc., which renders the puzzle difficult 
to be fully solved.
 Another focus of future work should be gaining 
more insight into mechanisms that might play a role 
in improved biomechanics or tissue organisation. A 
closer look at tissue remodelling at the wound site, 
what extracellular matrix components are present, 
as well as what tendon specific markers might be 
upregulated or downregulated during the treatment 
period with PDGF-BB, may offer knowledge as to 
how the healing might be affected and in turn how 
this can be used for better design of delivery devices 
or optimisation of application time.
Conclusion
Biological therapies after tendon ruptures or 
lacerations have many faces. Acceleration of the 
healing process with a true regeneration of the tendon 
tissue is a predominant desired aim. All cues leading 
to a faster cell infiltration to the wound site, with 
increased cell proliferation and accompanied with 
proper ECM remodelling are welcomed (Elliot and 
Giesen, 2013a; Elliot and Giesen, 2013b). Thus, the use 
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of growth factors delivered at the injury site, either 
single or applied as a cocktail of many (Nourissat et 
al., 2013), provides a promising approach to support 
the tendon healing process. Different growth factors 
including TGFβ1, PDGF, VEGF and fibroblast growth 
factor-2 (FGF-2) have been explored for tendon repair 
and have shown mixed responses of the regenerated 
tendons in terms of biomechanical and histological 
outcomes. VEGF was shown to have deleterious 
effect on tendon healing due to MMP-3-supported 
angiogenesis, with inferior biomechanical properties 
of the tendons (Sahin et al., 2012). Local delivery of 
TGFβ1 was shown to improve the biomechanical 
and histological properties of the tendons (Halper, 
2014; Majewski et al., 2012). However, TGFβ1 is a 
growth factor associated with complex biological 
signalling and scar and adhesion formation (Chang 
et al., 2000b; Galatz et al., 2006; Penn et al., 2012). 
Exogenous delivery of FGF-2 in a canine model did 
not result in improved biomechanical or molecular 
properties of the treated tendons (Thomopoulos et 
al., 2010b), on the other hand FGF-2 gene transfer has 
yielded more promising results (Tang et al., 2008). 
In comparison, and as summarised in this review, 
PDGF-BB with its clinical approval and biological 
properties represents a safe and promising growth 
factor to be applied as biological therapy in tendon 
rupture repair, administered either by bolus injection 
or incorporated in an implantable delivery device.
 From the literature covered in this review and 
the observations existing so far, it can be concluded 
that from the available delivery strategies, a single 
bolus injection of 10 µg of PDGF-BB one week 
post-operation (Shah et al., 2013) or a fibrin-based 
PDGF-BB delivery system loaded with much larger 
amounts than reported, e.g. 10 µg instead of only 
0.5 µg (Thomopoulos et al., 2009), would probably 
be the most promising approaches. However, for its 
potential to be fully exploited, crucial aspects like 
dosage, time of application and delivery method 
need to be carefully considered, chosen and further 
investigated in one and same in vivo model, while 
looking at many readouts as possible including 
biomechanics, inflammation and tissue remodelling.
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Discussion with Reviewer
Denitsa Docheva: How do the authors foresee the 
integration of PDGF-BB delivery devices, such as 
electrospinned polymers, once the healing process 
has been activated and the initial granulation tissue 
has been formed?
Authors: The way of PDGF-BB application one week 
after the operation is not meant to be performed 
by reopening the wound and manipulating for a 
second time. In contrast, delivery devices releasing 
the largest amount of PDGF-BB one week after the 
operation are desired systems. Partial degradation 
of the delivery device after the initial week should 
lead to highest PDGF-BB release at that point, as 
mentioned in “Current limitations and future work” 
paragraph.
 On the other hand, the in vivo performance 
of the delivery device, e.g. electrospun scaffolds, 
should be considered at the starting point, even 
before incorporating a growth factor. Careful and 
comprehensive degradation and integration studies 
of the devices must precede any further investigation. 
Cell infiltration and biomaterial encapsulation is how 
the integration of the electrospun scaffolds usually 
takes place and with time, if biodegradable, the 
material is degraded and reabsorbed.
 Our research group has used the polymer 
DegraPol® as a drug delivery device. As a first step, 
we investigated the effects in terms of in vivo cellular 
response towards this foreign material and focused 
on its integration. We found that it was very well 
accepted and no further inflammatory response 
was found. Moreover, in vivo, after 12 weeks , the 
degradation products were well integrated and 
penetrated by invading cells (Buschmann et al., 2013; 
Buschmann et al., 2015).
Editor’s note: The Scientific Editor responsible for 
this paper was Juerg Gasser.
